Madhav Bhutada says overdependence on large CDMOs and delayed engagement can increase development costs by up to 40% and slow clinical progress
The device screens for conditions like diabetic retinopathy, glaucoma, age-related macular degeneration, cataract and refractive error, in under ten minutes per patient
The company is expected to conduct further studies to confirm the long-term efficacy and safety of Vijoice in both adult and paediatric patients
If cleared, MAVIRET would become one of the few therapies in the European Union approved to treat both acute and chronic hepatitis C infections
The company said the breadth of its showcase reflects “progress from its differentiated oncology pipeline in solid tumors and hematologic malignancies,”
The new CRS offering is delivered from WACKER’s Biotechnology Center in Munich
This collaboration across the NIPER network- Raebareli, Hajipur, Ahmedabad and Hyderabad is strengthening translational research and opnMe access
The product has received tentative USFDA approval, Health Canada notice of compliance, and Indian regulatory approval
The country’s strength lies not just in technology availability but in adoption behaviour
Access to genomic testing, not therapy cost, is the biggest challenge
Subscribe To Our Newsletter & Stay Updated
